Magnetic medicine

(Johns Hopkins Medicine) Using tiny particles designed to target cancer-fighting immune cells, Johns Hopkins researchers have trained the immune systems of mice to fight melanoma, a deadly skin cancer. The experiments represent a significant step toward using nanoparticles and magnetism to treat a variety of conditions, the researchers say.
Source: EurekAlert! - Biology - Category: Biology Source Type: news

Related Links:

Conclusions: Whereas in myelodysplastic syndrome predominantly missense SRSF2 mutations are described, the observed SRSF2 mutations in UM are all in-frame deletions of 8–9 amino acids. This suggests that the R625 missense SF3B1 mutations and SRSF2 mutations in UM are different compared to the spliceosome gene mutations in hematological cancers, and probably target a different, as yet unknown, set of genes involved in uveal melanoma etiology.
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Communication Source Type: research
Authors: Hao J, Li S, Li J, Jiang Z, Ghaffar M, Wang M, Jia R, Chen S, Wang Y, Zeng Y Abstract Esophageal carcinoma (EC) is the sixth most deadly of all cancers. It is among the most malignant cancers due to its highly aggressive nature and low survival rate. The incidence of EC is high in Asia, particularly in Southern areas including China, Iran and Japan. There is a large body of evidence to suggest an association between the melanoma antigen gene (MAGE) family and the initiation of cancer; however, there is no clear evidence to suggest an association between EC and MAGE. Discovery of the chemical and physiologi...
Source: Experimental and Therapeutic Medicine - Category: General Medicine Tags: Exp Ther Med Source Type: research
rner Niels Schaft Chimeric antigen receptor (CAR)-T cells already showed impressive clinical regressions in leukemia and lymphoma. However, the development of CAR-T cells against solid tumors lags behind. Here we present the clinical-scale production of CAR-T cells for the treatment of melanoma under full GMP compliance. In this approach a CAR, specific for chondroitin sulfate proteoglycan 4 (CSPG4) is intentionally transiently expressed by mRNA electroporation for safety reasons. The clinical-scale protocol was optimized for: (i) expansion of T cells, (ii) electroporation efficiency, (iii) viability, (iv) cryopreser...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Technical Note Source Type: research
In this study we further explored the associations of these with melanoma, in addition to deprivation and socio-economic stressors. In this analysis of 2183 population-ascertained primary cutaneous melanoma patients; clinical, demographic and socio-economic variables were assessed as predictors of tumour thickness, melanoma death and overall death.
Source: Journal of Investigative Dermatology - Category: Dermatology Authors: Tags: Original Article Source Type: research
ConclusionPublic health strategies targeting this vulnerable group are currently needed in the Canary Islands (Spain).
Source: Cancer Epidemiology - Category: Cancer & Oncology Source Type: research
In conclusion, ITCH may downregulate GLUT1 and suppresses glucose uptake in melanoma to inhibit cancer cell proliferation. PMID: 31403357 [PubMed - as supplied by publisher]
Source: Journal of Dermatological Treatment - Category: Dermatology Tags: J Dermatolog Treat Source Type: research
FINDINGSCancer that has spread to the central nervous system is notoriously difficult to treat. Now, UCLA researchers have developed a drug delivery system that breaks through the blood-brain barrier in order to reach and treat cancer that has spread to the central nervous system.In research conducted in mice, a single dose of cancer drugs in a nanoscale capsule developed by the scientists eliminated all B-cell lymphoma that had metastasized to the animals ’ central nervous system.BACKGROUNDAbout 15% to 40% of all cancers spread to the nervous system, but there are few treatment options and they only work in a small ...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
Publication date: 2019Source: European Journal of Radiology Open, Volume 6Author(s): Andrea Borghesi, Andrea Tironi, Silvia Michelini, Alessandra Scrimieri, Diego Benetti, Roberto MaroldiAbstractMalignant melanoma is an aggressive cancer with a high metastatic potential. Among the multiple sites of metastatic disease, the lung is one of the most frequently involved sites. Typically, pulmonary metastases from malignant melanoma occur as solid nodules. Rarely, pulmonary involvement in metastatic melanoma occurs as subsolid nodules.The present article describes an unusual case of a patient with malignant melanoma that develop...
Source: European Journal of Radiology Open - Category: Radiology Source Type: research
Conditions:   Stage IV Non-small Cell Lung Cancer;   Stage IV Malignant Melanoma Intervention:   Other: Plasma sample collection Sponsor:   OncoHost Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Patients with mesothelioma are now eligible for a multicancer clinical trial studying the effectiveness of personalized immunotherapy at the University of California, San Diego Medical Center. The phase I clinical trial involves a combination of Keytruda (pembrolizumab), a proven immunotherapy drug, and an individualized vaccine based upon the genetic mutations found in each patient’s cancer. “This is the future of cancer treatment,” Dr. Ezra Cohen, principal investigator and director of the San Diego Center for Precision Immunotherapy, told The Mesothelioma Center at Asbestos.com. “Now, we still ha...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Biology | Cancer | Cancer & Oncology | Melanoma | Nanotechnology | Skin | Skin Cancer